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photothermalpropertiesof goldnanoparticles (AuNPs)with tar-
geted delivery using cell-speciﬁc DNA aptamers have a tremen-
dous potential for medical diagnostics and therapy of many
cell-based diseases. In this study, we demonstrate the high anti-
cancer activity of aptamer-conjugated, 37-nm spherical gold
nanoparticles toward Ehrlich carcinoma in tumor-bearing
mice after photothermal treatment. The synthetic anti-tumor
aptamers bring the nanoparticles precisely to the desired cells
and selectively eliminate cancer cells after the subsequent laser
treatment. To prove tumor eradication, we used positron emis-
sion tomography (PET) utilizing radioactive glucose and com-
puter tomography, followed by histological analysis of cancer
tissue. Three injections of aptamer-conjugated AuNPs and
5 min of laser irradiations are enough to make the tumor unde-
tectable by PET. Histological analysis proves PET results and
shows lower damage of healthy tissue in addition to a higher
treatment efﬁciency and selectivity of the gold nanoparticles
functionalized with aptamers in comparison to control experi-
ments using free unconjugated nanoparticles.
INTRODUCTION
Currently, gold nanoparticles (AuNPs) are of a great interest for can-
cer therapy, especially for thermal destruction of tumor cells, due to
their photothermal heating ability under laser irradiation and their
ability to be surface functionalized. Anti-cancer thermotherapy is
based on the high sensitivity of cancer cells to increased temperature.
Heating of a tumor up to +43.5S leads to irreversible denaturation of
proteins, while protein molecules in normal tissue remain intact.
AuNPs could serve as “optical heaters” and promote the destruction
of cancer cells.1 Oscillating electric ﬁelds of light propagating near a
colloidal nanoparticle interact with free electrons, causing a concerted
oscillation of an electron charge that is in resonance with the fre-
quency of visible (VIS) or near-infrared (NIR) light. The absorbed
light, converted to heat, generates localized hyperthermia and de-
stroys malignant cells. Photothermal therapy (PTT) is currently
considered to be a relatively noninvasive and benign alternative for1cancer treatment.2 To deliver nanoparticles to tumor sites, mono-
clonal antibodies (mAbs) are successfully used for the photodestruc-
tion of cancer cells and subsequent cell death.3 An alternative to an-
tibodies as a nanoparticle delivery vehicle is aptamers. Aptamers are
more preferable for the selective delivery of nanoparticles because of
their higher stability and lower immunogenicity. Recently, Shi et al.
reported a novel activatable theranostic nanoprobe based on ap-
tamers for in vivo cancer imaging and guided PTT.4 The authors
used a DNA aptamer previously selected against the A549 human
cancer cell line by Cell-SELEX to functionalize Au@Ag/Au NPs via
the thiol-gold bond to achieve speciﬁc NIR PTT. Due to the broad ab-
sorption spectra of Au@Ag/Au NPs and the expansion of aptamer
discovery for varying cancer targets, aptamer-modiﬁed gold nanopar-
ticles can be explored for the treatment of other cancer types.
In our study, we demonstrate the PTT activity of aptamer-conjugated
37-nm spherical gold nanoparticles (As42-AuNPs) toward Ehrlich
carcinoma cells in tumor-bearing mice (Figure 1). Nanoparticle heat-
ing was carried out by irradiation with visible, 536-nm laser light for
5 min. To prove the efﬁcacy of the aptamer-targeted hyperthermia,
positron emission tomography (PET) with radioactive glucose and
computer tomography (CT) with histopathological analysis of cancer
tissue were utilized.
RESULTS AND DISCUSSION
In Vitro Cancer Cell Hyperthermia with As42-AuNPs
AuNPs with an average diameter of 37 nm were used in this study.
The absorption spectra, Q(l), of AuNPs are shown in Figure 2.
Figure 1. Scheme of Selective Elimination of Cancer Cells In Vivo Using As42-AuNPs in Plasmonic Photothermal Therapy
As42-AuNPs are localized on the tumor cells after injection into amouse tail vein. Local irradiation of a tumor site with a green laser causes nanoparticle heating and cell death
followed by tumor eradication.Transmission electron microscopy images of AuNPs demonstrate
small variations in size and shape (Figure 2, insert). AuNPs were
chemically modiﬁed with the oligonucleotide containing a disulﬁde
group and subsequently hybridized with either the AS42 aptamer
or AG oligonucleotide as a non-speciﬁc control. The AS42 aptamer
was previously selected by our research group to live Ehrlich’s ascites
carcinoma cells with a dissociation constant, KD, of 2.5 nM.
5 A heat
shock cognate 71-kDa (HSPA8) protein was identiﬁed by protein
mass spectrometry as its binding partner. It is important to note
that the As42 aptamer has a high afﬁnity for the ascites cells but
does not cause apoptosis and does not interfere with cell division.
Therefore, the AS42 aptamer was picked for this study to facilitate tar-
geted delivery of nanoparticles and PTT of cancer cells. Laser irradi-
ation of cancer cells, without nanoparticles, at 532 nm for 10 min did
not signiﬁcantly heat (up to 38.4C) the cell suspension. However,
temperature increased up to 43.6C for the cells with As42-AuNPs
under the same laser irradiation conditions. The photothermal treat-
ment with As42-AuNPs resulted in 45% cell death, measured 3 hr
after laser irradiation. This can be attributed to the AS42 aptamer
bringing the AuNPs closer to the cancer cell’s surface (100 NPs
per cell), after which plasmon resonance caused local membrane hy-
perthermia, leading to cell death (Figure 3). In control experiments
using AG-AuNPs, the heat dissipated in solution because the AGoligonucleotide did not attach AuNPs to the cells. Laser irradiation
at 532 nm alone and in the presence of As42 aptamer without nano-
particles did not have an inﬂuence on cell viability in vitro. It is inter-
esting to note that nanoparticles modiﬁed with AG and As42
decreased the number of dead cells in the absence of irradiation
(Figure 3A).
Titration experiments with different concentrations of As42-AuNPs
(10, 50, 100, and 200 particles per cell [performed in triplicates]) re-
vealed that 100 As42-AuNPs per cell were enough to kill 83% ± 5% of
Ehrlich ascites cells, while 200 particles led to total necrosis in the cul-
ture (Figure 3B). Control liver and blood cells did not respond to plas-
monic PTT with As42-AuNPs, but the high density of nanoparticles
(200 per cell) caused necrosis of 6% ± 3% of the cells (Figure 3C).
Therefore, in order to increase the selectivity, a concentration of
100 As42-AuNPs per cell was chosen for further experiments.
The selectivity of the in vitro treatment with the As42-AuNPs has
been demonstrated using ﬂow cytometry experiments in a mixture
of Ehrlich carcinoma, blood, and liver cells. Before plasmonic photo-
thermal treatment with As42-AuNPs, it was conﬁrmed that Ehrlich
carcinoma cells (Figure 4A1), blood and liver cells (Figure 4A2),
and their mixture (Figure 4A3) were viable. Two hours after the ther-
apy, the majority of the carcinoma cells became necrotic (Figure 4B1),2
Figure 2. Absorption Spectra of Colloidal Solutions of AuNPs
Curves 1–3 correspond to the following concentrations: 1.1 , 1012 mL1 AuNPs;
4  1.1 , 109 mL1 AuNPs; and 5  1.1 , 108 mL-1 AuNPs, respectively. Dashed
line indicates the laser wavelength of 532 nm. Insert: transmission electron micro-
scopy (TEM) image of AuNPs.while most of the liver and blood cells stayed live (Figure 4B2). In the
mixture, carcinoma cells died, while liver and blood cells remained
viable (Figure 4B3).
Plasmonic PTT with As42-AuNPs in Mice
Mice implanted with solid Ehrlich carcinoma underwent PTT every
second day, starting from day 7 after tumor transplantation until
day 11. Changes in temperature at the surface of tumors were
controlled using thermography (Figure 5A). Interestingly, 532-nm
laser irradiation increased the temperature of the tumors in mice
treated with oligonucleotide-modiﬁed gold nanoparticles up to
46C, while mice injected with Dulbecco’s PBS (DPBS) experienced
a temperature rise of more than 40C. This is evidence for speciﬁc
and non-speciﬁc AuNPs concentrating at the tumor. Despite the
similar temperature increase in the case of As42-AuNP and AG-
AuNP treatments, aptamer-modiﬁed Au-NPs appeared to be more
effective because of their targeted delivery of AuNPs to the surface
of tumor cells. Changes in hip girth and tumor size, caused by the
thermal photoablation, depended on the injected substance and are
shown in Figure 5B. Hips of the mice injected with DPBS grew expo-
nentially, as expected. Additional laser irradiation resulted in
increased tumor development during the course of the experiment
(Figure 5B). This might be due to heating of the tumor, up to 40C,
by the laser. The administration of AG-AuNPs followed by irradia-
tion at 532 nm decreased tumor size in the subsequent group. Using
As42-AuNPs increased the effects of laser irradiation (Figure 4B3).
Administering As42-AuNPs without laser exposure slows down
tumor growth, somehow hindering cancer cell division. Necrotic
changes in treated and non-treated tumors were observed on day
13 after tumor transplantation (Figure 5C).3In order to control the last stages of tumor development after treat-
ment, we performed PET combined with CT (PET/CT) for one
mouse from each experimental group, since, visually, tumors treated
the same way were similar, and the girth of hips in relation to the
tumors did not differ. Histopathological examination of the tumors
was performed for every experimental mouse.
Since Ehrlich carcinoma cells actively consume glucose, the viability
and functional state of this tumor could be assessed with the help
of the radionuclide method of functional diagnostics (PET/CT) using
the radiopharmaceutical [18F]-ﬂuorodeoxyglucose. [18F]-ﬂuorodeox-
yglucose is a biological analog of glucose and penetrates from the
vascular into the extracellular space and then into the cells, where it
is phosphorylated by hexokinase. The reaction product is [18F]-deox-
yglucose-6-phosphate. Unlike glucose phosphate, [18F]-deoxyglu-
cose-6-phosphate does not enter into further reactions and remained
in the cells during the study, which allowed the accumulation and
measurement of the radionuclide in the growing tumor.6
On day 6 after tumor transplantation and before the AuNP treatment
and laser irradiation, the tumor showed a 17 mm  15 mm homoge-
neous structure with tissue density (45–50 Hounsﬁeld units [HU])
and actively accumulated [18F]- ﬂuorodeoxyglucose (Figure 6A).
The glucose was also accumulated in the bladder and liver of this
mouse. Histopathological examination of untreated tumors showed
that the tumors of all mice had homogeneous solid structures
throughout the volume; inﬂammatory response was low, carcinoma
cells inﬁltrated and replaced the skeletal muscle tissue, and the tumor
recruited new blood vessels (Figure S1A).
In a control mouse after injection of DPBS, the tumor grew 25%more,
reaching a size of 23 mm  19 mm on day 14. Its structure was non-
uniform, and density varied from 25 to 50 HU, with indistinct con-
tours and a high level of accumulation of radiopharmaceutical
[18F]-ﬂuorodeoxyglucose (Figure 6B). Moreover, a metastasis in the
testicle of the examined mouse was detected. The bladder of this
mouse was empty, so there was no glucose accumulation (Figure 6B).
Histopathological analyses of tumors in the hips revealed relatively
intact tumors (Figure S1B) composed of viable atypical cells with
pleomorphic nuclei of different shapes and cytoplasmic volumes
(Figures 7A and 7B).
After the third treatment with DPBS injection, followed by laser irra-
diation in the right leg, the tumor had the size of 20 mm  17 mm,
and its large part (16 mm  10 mm) presented a non-metabolic
necrotic area (Figure 6C). Radiopharmaceutical accumulation was
4–5 mm in diameter, located in the upper inner part of the tumor.
[18F]-ﬂuorodeoxyglucose was also accumulated in the bladder of
this mouse (Figure 6C). Tumors of all experimental mice were
massive with swelling, small ulcers (Figure 5C). Tissues had heteroge-
neous structures (Figure S1C), sites of necrosis with complete loss of
tissue structure, but without sufﬁcient inﬂammation (Figures 7C and
7D). Probably, the lack of new blood vessels in the tumor and laser
heating to 40C resulted in necrotic changes.
Figure 3. Effects of Photothermal Therapy of Ehrlich Carcinoma Cells Depending on the Presence of Gold Nanoparticles and/or DNA Aptamers In Vitro
(A) Portions of dead cells were measured using trypan blue 3 hr after treatment in different experimental models. 1, intact Ehrlich carcinoma cells; 2, Ehrlich carcinoma cells
after a 4-min laser irradiation; 3, Ehrlich carcinoma cells incubated with As42-AuNPs; 4, Ehrlich carcinoma cells preincubated with As42-AuNPs after 4 min of irradiation; 5,
Ehrlich carcinoma cells incubated with free aptamer As42; 6, Ehrlich carcinoma cells incubated with free aptamer As42 after 10 min of irradiation; 7, Ehrlich carcinoma cells
incubated with AG-AuNPs; 8, Ehrlich carcinoma cells incubated with AG-AuNPs after 4 min of irradiation. (B) Viability of Ehrlich cells after plasmonic photothermal therapy
in vitro with As42-AuNPs (in the ratios of 10, 50, 100, and 200 AuNPs per cell). (C) Viability of liver and blood cell mixture after plasmonic photothermal therapy in vitro with
As42-AuNPs (in the ratios of 10, 50, 100, and 200 AuNPs per cell). PI, propidium iodide. (D) Schematic representation of the Ehrlich, liver, and blood cell viability mea-
surements after plasmonic photothermal treatment. All data are presented as the mean ± SEM.Three treatment procedures with non-speciﬁc oligonucleotide AG-
AuNPs followed by 532-nm laser irradiation resulted in visual tu-
mor size reduction. PET indicated that the tumor was reduced in
size by 18%, to 14 mm  12 mm, with a density of 35–42 HU (Fig-
ure 6D). The tumor had a heterogeneous structure and moderateswelling (Figure S1D). All mice in this group had ulcerative defects
(Figures 5CIII and 7E) and necrotic changes located under skin
dermis (Figure 7E). In the center of the tumor, necrotic areas
were found in the form of islands with completely destructed cells
(Figure 7F). Dead (Figure 7G) and viable (Figure 7H) leukocytes4
Figure 4. Selectivity of Plasmonic Photothermal Therapy In Vitro
(A) Necrosis in (1) intact Ehrlich carcinoma cells; (2) a liver and blood cell mixture (flow cytometry density plots); and (3) amixture of Ehrlich carcinoma, liver and blood cells (flow
cytometry dot plot). (B) Necrosis in (1) Ehrlich carcinoma cells; (2) a liver and blood cell mixture; and (3) a mixtue of Ehrlich carcinoma, liver, and blood cells (flow cytometry dot
plots) after plasmonic photothermal therapy. (C) Schematic representation of (C1) necrotic Ehrlich carcinoma cells; (C2) intact liver and blood cells; and (C3) a mixture of
Ehrlich carcinoma, liver, and blood cells after photothermal treatment.dominated in the inﬂammatory inﬁltrates and surrounded the
viable carcinoma areas.
The treatments with As42-AuNPs and laser irradiation eliminated
tumors almost completely, as seen in PET/CT images (Figure 6E).
All mice had big ulcers in the tumor sites. Based on histopathological
analysis, the tumor sites were mostly necrotic, with high leukocyte
inﬁltration (Figure 7K). Figure 7 shows therapeutic effects in details:
necrosis of the skin and underlying tumor, the loss of the epidermis,
and bleeding of the dermis (Figures 7I–7K). Dead cancer cells had the5characteristic signs of karyopyknosis, karyorhexis, and autolysis
(Figure 7L). Although in the center, the tumor looked viable in the
histological sections (Figure S1E), it was not metabolically active;
according to PET analyses, the cells did not accumulate [18F]-ﬂuoro-
deoxyglucose (Figure 6E).
Some nonspeciﬁc accumulation of [18F]-ﬂuorodeoxyglucose was
observed near the mouse tail vein and bladder. This is due to the
administration of the radiopharmaceutical into the mouse tail vein
in a physiological saline solution that is excreted in urine.
Figure 5. Targeted Plasmonic Photothermal Therapy In Vivo
(A) Thermal images of mouse hips after tail-vein injection of DPBS (AI), AG-AuNPs (AII) modified, or AS42-AuNPs (AIII) after 5 min of laser irradiation at 1.2 W. (B) Changes in
the hip girth within tumors. The treatment has been performed on days 7, 9, and 11. (C) The representative images of the tumors of treated and non-treated mice are on day
11 treated with (I) DPBS only; (II) DPBS and 5 min of laser irradiation, (III) AG-AuNPs and 5 min of laser irradiation (IV) AS42-AuNPs and 5 min of laser irradiation. All data are
presented as the mean ± SEM.Hepatotoxicity of As42-AuNPs was monitored by measuring stan-
dard blood serum biochemistry parameters such as cholesterol, serum
alanine amino-transferase (ALT), alkaline phosphatase (AST), and
bilirubin (Table 1).7 ALT is involved in energy metabolism in liver,
total bilirubin is a marker of hepatobiliary injury and hemolysis,
and ALP indicates hepatocyte damage. Healthy male and female
mice underwent three treatment procedures every other day with
As42-AuNPs. This did not cause signiﬁcant changes in blood
biochemical parameters, compared to the control group treated
with DPBS, and did not depend on gender. Inﬂammation and hydra-
tion status after the treatment with nanoparticles were evaluated by
the total protein concentration (Table 1). All tested parameters indi-
cated that treatment with As42-AuNPs was safe and did not cause un-
wanted hepatotoxic effects.
DISCUSSION
Plasmonic PTT represents the least invasive method of malignant
neoplasia treatment. This method uses the conversion of the photon’s
energy into thermal energy sufﬁcient for tumor destruction. The use
of hyperthermia is the most promising for cases when surgicalremoval of a tumor is challenging. Our study shows photothermal
destruction of Ehrlich’s ascites carcinoma cells using AuNPs func-
tionalized with DNA aptamers. Using the tumor-speciﬁc aptamers
enables precise delivery of AuNPs to the membrane of a target cells
and enhances the speciﬁcity of photothermotherapy. Laser irradiation
resonantly excites plasmons and produces the heating effect of
AuNPs, causing damage to cancer target cells while leaving healthy
cells untouched. One can expect aptamer-functionalized AuNPs
to bind selectively to cancer cells and result in the localization of
AuNPs within a tumor, which is necessary for the enhancement of
therapeutic treatment efﬁciency and suppression of lateral negative
effects, such as possible overheating of the healthy cells and tissues.
Aptamer-functionalized AuNPs possess a series of additional advan-
tages; particularly, they are stable against aggregation by negative
charges of oligonucleotides, and they do not form conglomerates
inside blood vessels. Moreover, in contrast to protein antibodies,
aptamer-functionalized AuNPs are practically non-immunogenic,
and any loss of conﬁrmation that such drugs might experience due
to storage conditions can be easily reversed with no loss in quality.6
Figure 6. PET/CT and Histopathological Images of Mice after PPT Treatments
(A–E) PET/CT images of mice before PPT treatment (A); after treatment with DPBS without laser irradiation (B); after PPT therapy with DPBS (C), AG-AuNPs (D), and AS42-
AuNPs (E). Red arrows indicate accumulation of 18[F]-fluorodeoxyglucose; green arrow indicate necrosis and swelling.Despite the aforementioned advantages, we faced some drawbacks
related to the fact that tumor cells, as we proved, are destructed via
necrosis, which led to high levels of inﬂammation in the organism.
Adjusting the power and selection of a softer regime of laser irradia-
tion allows ﬁnding a gentler mode of laser thermal destruction. In this
mode, tumor cells die slowly without the development of the hyper-
active inﬂammatory process.
In conclusion, the present work demonstrates, for the ﬁrst time, the
use of AuNPs functionalized by aptamers for plasmonic PTT. Further
research can focus on the development of the particles possessing NIR
plasmon resonance for deeper treatment of tumors.
MATERIALS AND METHODS
Chemicals and Materials
DNA probes were custom designed and synthesized by Integrated
DNA Technologies, USA. DPBS, CELLSTAR in DMEM, trypan
blue, and fetal bovine serum (FBS) were purchased from Sigma-
Aldrich, USA. AuNPs, with an average diameter of 37 nm, were pur-
chased from BioTest, Novosibirsk, Russia.
Animals
Male white, 6-week-old 25 g Imprinting Control Region (ICR) mice
were purchased from Siberian Federal University, Krasnoyarsk,
Russia. Tumor-bearing animals were prepared through intramus-
cular injection of two million Ehrlich carcinoma cells into the right
leg of the mice. Tumors were then allowed to grow for 5 days. On
days 5, 7, and 9 after the tumor transplantation using 2 106 Ehrlich
carcinoma cells, all animals were treated with aptamer-functional-
ized, gold-coated magnetic nanoparticles.
This study was carried out in strict accordance with the recommen-
dations in the NIH Guide for the Care and Use of Laboratory Ani-
mals. The protocol was approved by the Local Committee on the
Ethics of Animal Experiments of the Krasnoyarsk State Medical
University. All procedures were performed under anesthesia, and
all efforts were made to minimize the suffering of the animals.7Cell Culture
For the in vitro studies, a mouse Ehrlich carcinoma cell culture was uti-
lized. The mouse ascites cells were cultured in 35 10-mm cell-culture
dishes (CELLSTAR) in DMEM supplemented with 100 U mL1 peni-
cillin, 100 U mL1 streptomycin, and 5% (v/v) FBS in a humidiﬁed
atmosphere containing 5%CO2 at 37C. All cell experiments were per-
formed in DPBS containing 0.9 mM CaCl2 and 0.49 mM MgCl2.
Functionalization of Gold Nanoparticles with DNA Aptamers
AuNPs with an average diameter of 37 nm were used in this study.
Extinction spectra of conjugates of AuNPs with the DNA aptamer
were recorded using a UV-3600 spectrophotometer (Shimadzu,
Japan).
Nanoparticle stabilization was carried out with a thiolated probe:
a high-performance liquid chromatography (HPLC)-puriﬁed oligo-
nucleotide 50-CGT GGT TAC AGT CAG AGG AGA A-/ThioMC6-
D/-30 modiﬁed at the 30 end with a 6-hydroxyhexyl disulﬁde group
(Integrated DNA Technologies, USA) in AuNP storage buffer for
24 hr at 4C on a shaker (ﬁnal concentration, 500 nM). This thiolated
probe was complimented to the 50 end of the AS42 aptamer: 50-CTC
CTC TGA CTG TAA CCA CGT CAA TGG GTG ATA TAT GCA
GGT TAC GCT GGC TAG TTG AAA GCA TAG GTA GTC CAG
AAG CC-30. This mixture was diluted 2 times by mixing it with
DPBS (with calcium and magnesium) and then with an equimolar
amount of the AS42 aptamer or the AG oligonucleotide: 50-CTC
CTC TGA CTG TAA CCA CG (AG)20 GCA TAG GTA GTC CAG
AAG CC-30 as a nonspeciﬁc control and incubated for an additional
24 hr on a shaker. Prior to use, oligonucleotides were heated at 95C
for 10 min and cooled on ice for 10 min.
In Vitro Analyses of PTT
One million mouse Ehrlich carcinoma cells in 1 mL colorless high-
glucose DMEM were used for the in vitro analyses.
A continuous-wave Millennia V laser (Spectra-Physics Lasers, USA)
was used for excitation of plasmon resonance of AuNPs at 532 nm.
Figure 7. Histopathological Assessment of Solid Ehrlich Carcinoma Tumor
H&E staining. Representative sections were obtained after PPT with DPBS only. (A) Carcinoma under epidermis. (B) General view of mouse carcinoma treated with DPBS
only. Magnification, 200. PPT with DPBS and 5 min of laser irradiation. (C) General view of the tumor under epidermis. (D) The border between relatively intact viable and
necrotic (asterisk) tumor tissues lacking inflammatory cells. Magnification, 100. PPT with AG-AuNPs and 5 min of laser irradiation. (E) Ulcerative defect. (F) Scab (arrow) in
the bottom of the wound and tumor necrosis under the dermis (asterisk). Magnification, 50. (G) Complete destruction of tumor tissue in the center of the necrotic area
(asterisk). Mostly dead segmented leukocytes (arrow). Magnification,100. (H) Inflammatory infiltration of segmented leukocytes at the tumor border (arrow). Magnification,
100. PPT with As42-AuNPs and 5 min of laser irradiation. (I) Ulcerative defect, carcinoma necrosis (asterisk) in the bottom under the wound. (J) Necrosis of the skin and
underlying tumor (asterisk), the loss of the epidermis (arrow), and the dermis bleeding (arrows). Magnification, 50. (K) The boundary of the tumor necrosis in the dermis is
separated with the area of leukocyte infiltration (arrow), outside of which hemocirculatory disorder takes place. Magnification, 50. (L) Tumor necrosis (asterisk) is char-
acterized by karyopyknosis, karyorhexis, and autolysis. Magnification, 100.The cuvette with the solution was placed in the region where the
diameter of the laser beam was equal to 2 cm; the temperature of
the suspension was monitored using a thermal imager. Laser power
was set to be 2.5W, and exposition time was 10 min per session. Eight
samples containing 106 cells were prepared and treated as follows:
intact cells (106 cells per milliliter) in 1 mL; cells after 10-min laser
irradiation at a 532-nm wavelength; cells incubated with As42-
AuNPs (108 particles per milliliter); cells incubated with As42-AuNPs
(108 particles per milliliter) for 30 min followed by 10-min laser irra-
diation at a 532-nm wavelength; cells incubated with the aptamer
As42 (500 nM) for 30 min; cells incubated with the aptamer As42
(500 nM) for 30 min followed by 10-min laser irradiation at a
532-nm wavelength; cells incubated with AG-AuNPs (108 particles
per milliliter); and cells incubated with AG-AuNPs (108 particlesper milliliter), followed by 10-min laser irradiation at a 532-nm wave-
length. The samples with the cells were incubated at 37C in a humid-
iﬁed atmosphere containing 5% CO2 before and after irradiation. All
samples were prepared in three replicates.
Determination of the percentage of damaged cells was performed 3 hr
after the laser irradiation using 0.4% trypan blue (Sigma-Aldrich,
USA).
In Vivo Analyses of PTT
Six-week-old, 25-g ICR male mice were used in this study; ﬁve ani-
mals per group. For 2 weeks before the experiments, animals were
trained to stay calm when being handled and inside the test cage.
Two million Ehrlich carcinoma cells were transplanted into the right8
Table 1. Blood Serum Biochemistry Parameters Performed for Male and Female Mice Treated with As42-AuNPs in DPBS or with DPBS Alone
Sample Cholesterol (mmol/L1) Total Protein (g/L1) Alanine Amino-Transferase (IU/L1) Alkaline Phosphatase (IU/L1) Total Bilirubin (mmol/L1)
As42-AuNPs
Female (N = 5) 1.49 ± 0.33 47.85 ± 3.46 18.40 ± 5.67 263.30 ± 94.81 5.90 ± 0.51
Male (N = 5) 1.91 ± 0.50 49.83 ± 5.21 21.1 ± 7.17 289.76 ± 103.09 6.01 ± 0.41
DPBS
Female (N = 5) 2.0 ± 0.30 52.09 ± 1.28 14.05 ± 5.73 206.61 ± 57.13 6.06 ± 0.58
Male (N = 5) 2.20 ± 0.28 56.10 ± 2.06 20.03 ± 6.01 256.30 ± 78.25 6.30 ± 0.65
All data are presented as the mean ± SEM.leg of each mouse. Every second day, starting from day 7 after tumor
transplantation until day 11, animals underwent PTT. A continuous-
wave Millennia V laser was used for excitation of plasmon resonance
of AuNPs at 532 nm. Fur from the mice legs with the tumors were
removed using Veet hair removal cream (Reckitt Benkiser, France).
The animal was placed into an experimental cage with the tumor
leg outside the region where the diameter of the laser beam was equal
to 2 cm; the temperature of the leg was monitored using an infrared
camera (Testo 875-1i from TESTO, Germany). Laser power was set to
be 2.5 W, and exposition time was 5 min per session.
Tail-vein injections for the mice randomly divided into ﬁve groups
(on days 7, 9, and 11 after the tumor transplantation, 3 times total)
were as follows:
Group 1: injection of 100 mL DPBS;
Group 2: injection of 100 mL DPBS followed by 5-min laser irra-
diation;
Group 3: injection of As42-AuNPs in 100 mL DPBS (1.1 mg/kg1;
50 particles per cell);
Group 4: injection of As42-AuNPs in 100 mL DPBS (1.1 mg/kg1;
50 particles per cell) followed by 5-min laser irradiation; and
Group 5: injection of AG-AuNPs in 100 mL DPBS (1.1 mg/kg1;
50 particles per cell) followed by 5-min laser irradiation.
After 30min, animals were placed inside the test cage, and the leg with
the tumor stayed outside and was irradiated with the 532-nm laser for
5 min.
PET/CT
Tumor volumes were monitored using PET/CT. On day 6 (before the
ﬁrst treatment) and day 12 after tumor transplantation (the next day
after the third treatment procedure), animals were injected intrave-
nously with 4–6 MBq (0.11–0.16 mCi) [18F]-ﬂuorodeoxyglucose,
followed by a PET/CT scan 1 hr after injection. Animals under anes-
thesia (ketamine/xylazine: intraperitoneal dose at 70 mg/kg of keta-
mine and 5–12 mg/kg xylazine) were ﬁxed for imaging. The study
was conducted with a Discovery PET/CT 600 scanner (General Elec-
tric, USA) and consisted of CT in a spiral mode with 3.75-mm layer9thickness followed by post-reconstruction with a 0.625-mm slice.
Afterward, positron emission scanning was done in 3D mode for
5 min with iterative reconstruction of the acquired images. Obtained
data were analyzed using PET VV software at an AWVolume Share 5
work station. Efﬁciency of the treatment was estimated by tumor
localizations, contours, sizes, and the degree of [18F]-ﬂuorodeoxyglu-
cose accumulation. CT images were analyzed using the Hounsﬁeld
densitometry scale.
Tissue Analysis
Microscopy analyses of the tumor tissue sections were performed in
order to evaluate histological changes of the tumors. Tumors were
harvested and placed in 3.7% formalin on the day following the last
treatment procedure. Tumor tissue sections for staining were pre-
pared using the HM 525 cryostat. The tissue sections were ﬁxed
onto a glass polylysine slide and stained with H&E dyes by the stan-
dard Blickmethod. Finally, sections were imaged with an Axio Imager
A1 optical microscope and an AxioCam MRc 5 high-resolution
camera (Carl Zeiss, Germany). Magniﬁcation was 50, 100,
200, and 400.
In Vivo Toxicity of Aptamer-Modified AuNPs
Six-week-old, 25-g ICR male mice were used in this study; 10 animals
per group. The tail-vein injections on themice (5 female and 5male in
each group) were performed on days 1, 3, and 5 (3 times total) were as
follows:
Group 1: injections of As42-GMNPs in 100 mL DPBS (1.6 mg/kg);
and
Group 2: injections of 100 mL DPBS.
Toxicity was estimated by the changes in blood biochemistry (choles-
terol, total protein, ALT, AST, and bilirubin); this was performed
using the COBAS INTEGRA 400 plus analyzer (Roche Diagnostics,
Switzerland). Parameters for male and female mice were analyzed
separately. All data were presented as the mean ± SEM.
Identification of Aptamer’s Binding Partner
Identiﬁcation of the binding partner of the aptamer As42 was done
using a protocol previously demonstrated by Zamay et al.8 In brief,
protein binding partners have been puriﬁed from the cell lysate using 
magnetic separation with 1 mg Streptavidin MagneSphere Paramag-
netic Particles (Promega, USA) and identiﬁed by mass spectrometric 
analysis of 10 mL protein-digest using nanoﬂow ultra-high-pressure 
liquid chromatography (Easy-nLC 1000, Thermo Scientiﬁc) and 
tandem mass spectrometry with an Orbitrap Velos Pro mass spec-
trometer (Thermo Scientiﬁc). Mathematical analyses were done 
with the Proteome Discoverer 1.3 software, Sequest search engine 
and SwissProt database, and MaxQuant 1.4 proteomic software. 
Experiments were performed in triplicates.
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